Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience

Overview

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with one of genitourinary tumors & treatment outcomes in these patients.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: March 2022

Detailed Description

Background: Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the adult urologic practice, but are relatively infrequent in children. Genitourinary tumors contribute to pediatric solid tumors. Wilms tumor, rhabdomyosarcoma, and germ cell tumors are the most common malignant genitourinary tumors in children. The natural history and management of these tumors in the pediatric age is different from that of the adults. As result of the successful work of several clinical trial groups in recent decades, there has been a significant improvement in their cure rates. Patients & Methods: From January 2001 till December 2015, retrieval & analysis of the medical records of pediatric patients with genitourinary tumors will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.

Clinical Trial Outcome Measures

Primary Measures

  • Overall survival (OS)
    • Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
    • Time from the date of initiation of treatment until death from any cause
  • Event Free Survival (EFS)
    • Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
    • Time from the date of initiation of treatment until disease progression, or death for any reason.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients whose age less than or equal to 18 years. – Patients diagnosed with any of neoplasms affecting the genitourinary system. Exclusion Criteria:

  • Patients whose age more than 18 years.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Assiut University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Ahmed Mohammed Morsy, MD, Lecturer, Pediatric Oncology Department – Assiut University

References

Dénes FT, Duarte RJ, Cristófani LM, Lopes RI. Pediatric genitourinary oncology. Front Pediatr. 2013 Dec 16;1:48. doi: 10.3389/fped.2013.00048. Review.

Lambert S. Adult Survivors of Pediatric Genitourinary Tumors. In: Wood HM, Wood D, editors. Transition and Lifelong Care in Congenital Urology: Springer International Publishing; 2015. p. 209-16.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.